Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. PMN
PMN logo

PMN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
22.400
Open
21.860
VWAP
20.83
Vol
38.07K
Mkt Cap
43.24M
Low
20.000
Amount
793.00K
EV/EBITDA(TTM)
--
Total Shares
2.15M
EV
31.25M
EV/OCF(TTM)
--
P/S(TTM)
--
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Show More

Events Timeline

(ET)
2026-01-30
09:40:00
Promis Neurosciences Inc Trading Halted
select
2025-12-18 (ET)
2025-12-18
07:40:00
ProMIS Neurosciences Completes Enrollment of 144 Patients in Clinical Trial
select
2025-12-10 (ET)
2025-12-10
07:50:00
ProMIS Neurosciences Publishes Alzheimer's Research Findings
select
2025-12-01 (ET)
2025-12-01
08:50:00
H.C. Wainwright Raises ProMIS Price Target to $18 from $4
select
2025-11-24 (ET)
2025-11-24
08:23:52
ProMIS Neurosciences declares a 1-for-20 reverse stock split.
select
2025-11-12 (ET)
2025-11-12
07:15:27
ProMIS Neurosciences announces Q3 earnings per share of 24 cents, down from 31 cents a year ago.
select
2025-09-03 (ET)
2025-09-03
07:02:27
ProMIS Secures DSMB Approval to Move Forward with Final Dose Escalation Group
select

News

Yahoo Finance
9.5
01-18Yahoo Finance
Phoenix Mecano Valued at CHF 769, Currently 44% Undervalued
  • Intrinsic Value Assessment: Utilizing a two-stage discounted cash flow model, Phoenix Mecano's intrinsic value is estimated at CHF 769, indicating a 44% undervaluation compared to its current share price of CHF 434, reflecting conservative market expectations for future cash flows.
  • Future Cash Flow Forecast: The projected free cash flow is expected to grow annually, starting at €28.3 million in 2026 and reaching €57 million by 2035, indicating strong growth potential in the company's profitability and cash generation capabilities.
  • Terminal Value Calculation: The estimated terminal value is €887 million, with a present value of €452 million, demonstrating the company's stable growth potential in the long term despite market volatility and industry cyclicality risks.
  • Investment Risk Warning: While the company shows strong dividend performance, it has experienced a decline in earnings over the past year, and revenue growth is expected to be below 20%, necessitating investor attention to these potential risks when assessing investment value.
NASDAQ.COM
2.0
2025-12-19NASDAQ.COM
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
  • Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.

  • Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.

  • MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.

  • DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.

NASDAQ.COM
2.0
2025-12-09NASDAQ.COM
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
  • Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.

  • Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.

  • Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.

  • Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.

Globenewswire
1.0
2025-12-01Globenewswire
ProMIS Neurosciences CEO to Participate in Evercore Healthcare Conference on December 2, 2025
  • Conference Participation: ProMIS Neurosciences CEO Neil Warma will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025, showcasing the company's advancements in Alzheimer's disease treatment, which is expected to attract investor interest.
  • Product Candidate: PMN310, ProMIS's lead product candidate, is designed to selectively target toxic oligomers associated with Alzheimer's disease, potentially reducing the risk of amyloid-related imaging abnormalities and improving treatment safety and efficacy.
  • Clinical Trial Launch: Following encouraging results from initial trials, ProMIS has initiated the PRECISE-AD clinical trial to evaluate the safety and tolerability of multiple doses of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease, which is expected to provide critical data for clinical application.
  • Technology Platform: ProMIS's EpiSelect™ platform identifies toxic misfolded proteins associated with neurodegenerative diseases, facilitating the development of antibodies and vaccines targeting these specific epitopes, demonstrating the company's innovative capabilities and market potential in the biotechnology sector.
Benzinga
4.5
2025-11-24Benzinga
Dow Rises by 300 Points; Waldencast Stock Takes a Dive
  • U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.

  • Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.

  • Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.

  • Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.

Benzinga
4.5
2025-11-24Benzinga
Nasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly
  • U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 350 points, while the Dow and S&P 500 also saw increases of 0.16% and 0.83%, respectively.

  • Sector Movements: Communication services stocks rose by 2.7%, while energy stocks experienced a decline of 0.9%.

  • Company Earnings Highlights: CureVac N.V. reported better-than-expected third-quarter earnings of $1.41 per share and sales of $63.295 million, surpassing analyst estimates.

  • Market Reactions: Enlivex Therapeutics shares surged 79% following a significant private placement announcement, while Clearside Biomedical shares plummeted 67% after filing for bankruptcy.

Wall Street analysts forecast PMN stock price to rise
3 Analyst Rating
Wall Street analysts forecast PMN stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
18.00
Averages
29.33
High
35.00
Current: 0.000
sliders
Low
18.00
Averages
29.33
High
35.00
Guggenheim
Eddie Hickman
Buy
downgrade
$6 -> $5
AI Analysis
2025-11-18
Reason
Guggenheim
Eddie Hickman
Price Target
$6 -> $5
AI Analysis
2025-11-18
downgrade
Buy
Reason
Guggenheim analyst Eddie Hickman lowered the firm's price target on ProMIS Neurosciences to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences' Alzheimer's candidate, PMN310, is rapidly advancing toward key clinical milestones, which keeps the company on track for two pivotal data readouts in 2026, the analyst tells investors following the company's Q3 report.
H.C. Wainwright
Raghuram Selvaraju
initiated
$4
2025-07-14
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$4
2025-07-14
initiated
Reason
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PMN
Unlock Now

Valuation Metrics

The current forward P/E ratio for ProMIS Neurosciences Inc (PMN.O) is -0.69, compared to its 5-year average forward P/E of -1.14. For a more detailed relative valuation and DCF analysis to assess ProMIS Neurosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.14
Current PE
-0.69
Overvalued PE
0.52
Undervalued PE
-2.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.16
Undervalued EV/EBITDA
-2.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2204.37
Current PS
0.00
Overvalued PS
6642.98
Undervalued PS
-2234.24

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

positive macd and expanding
Intellectia · 1739 candidates
Region: USList Exchange: XNYS, XNAS, XASEMacd: positive, bullish
Ticker
Name
Market Cap$
top bottom
WTO logo
WTO
UTime Ltd
1.13M
PZG logo
PZG
Paramount Gold Nevada Corp
163.38M
DVA logo
DVA
DaVita Inc
9.26B
GORO logo
GORO
Gold Resource Corp
250.87M
CDT logo
CDT
CDT Equity Inc
2.68M
DSS logo
DSS
DSS Inc
11.68M
low float, price between 2 and 20, rvol > 5.
Intellectia · 28 candidates
Price: $2.00 - $20.00Relative Vol: >= 5
Ticker
Name
Market Cap$
top bottom
GPAC logo
GPAC
General Purpose Acquisition Corp
284.28M
PMN logo
PMN
ProMIS Neurosciences Inc
30.48M
MOGU logo
MOGU
Mogu Inc
19.37M
ILAG logo
ILAG
Intelligent Living Application Group Inc
7.15M
VIVS logo
VIVS
VivoSim Labs Inc
7.62M
ELPW logo
ELPW
eLong Power Holding Ltd
58.63M
low float. price between 2 and 20.
Intellectia · 908 candidates
Price: $2.00 - $20.00Floating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
ELPW logo
ELPW
eLong Power Holding Ltd
58.63M
VIVS logo
VIVS
VivoSim Labs Inc
7.62M
ASBP logo
ASBP
Aspire Biopharma Holdings Inc
7.37M
BUUU logo
BUUU
BUUU Group Ltd
191.60M
MOGU logo
MOGU
Mogu Inc
19.37M
CNCK logo
CNCK
Coincheck Group NV
388.75M
low float high volume
Intellectia · 49 candidates
Region: USVolume: >= 500,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
FAT logo
FAT
FAT Brands Inc
5.25M
APRE logo
APRE
Aprea Therapeutics Inc
5.57M
FATBB logo
FATBB
FAT Brands Inc
27.81M
YCBD logo
YCBD
cbdMD Inc
10.92M
LXEH logo
LXEH
Lixiang Education Holding Co Ltd
6.50M
KXIN logo
KXIN
Kaixin Holdings
29.77M
stocks with short squeeze
Intellectia · 297 candidates
Short Ratio: MoreThan30PctList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PMN logo
PMN
ProMIS Neurosciences Inc
25.87M
PHGE logo
PHGE
Biomx Inc
8.95M
SGMO logo
SGMO
Sangamo Therapeutics Inc
164.85M
ATYR logo
ATYR
aTyr Pharma Inc
82.28M
MOD logo
MOD
Modine Manufacturing Co
9.83B
LDWY logo
LDWY
Lendway Inc
8.42M

Whales Holding PMN

D
Deep Track Capital, LP
Holding
PMN
-6.45%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is ProMIS Neurosciences Inc (PMN) stock price today?

The current price of PMN is 20.09 USD — it has decreased -7.38

What is ProMIS Neurosciences Inc (PMN)'s business?

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

What is the price predicton of PMN Stock?

Wall Street analysts forecast PMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is29.33 USD with a low forecast of 18.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ProMIS Neurosciences Inc (PMN)'s revenue for the last quarter?

ProMIS Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is ProMIS Neurosciences Inc (PMN)'s earnings per share (EPS) for the last quarter?

ProMIS Neurosciences Inc. EPS for the last quarter amounts to -5.93 USD, decreased -176.91

How many employees does ProMIS Neurosciences Inc (PMN). have?

ProMIS Neurosciences Inc (PMN) has 6 emplpoyees as of March 12 2026.

What is ProMIS Neurosciences Inc (PMN) market cap?

Today PMN has the market capitalization of 43.24M USD.